Congestive heart failure AHA recommendations for patients with a prior MI: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(/* ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Left Ventricular Dysfunction Due to Prior Myocardial Infarction (DO NOT EDIT) {{cite journal| author=Zipes DP, Camm...)
No edit summary
 
(13 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Infobox_Disease |
{| class="infobox" style="float:right;"
  Name          = Heart failure |
|-
  Image          = |
| [[File:Siren.gif|30px|link= Congestive heart failure resident survival guide]]|| <br> || <br>
  Caption        = |
| [[Acute decompensated heart failure resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']]
  DiseasesDB    = 16209 |
|}
  ICD10          = {{ICD10|I|50|0|i|50}} |
{| class="infobox" style="float:right;"
  ICD9          = {{ICD9|428.0}} |
|-
  ICDO          = |
| [[File:Critical_Pathways.gif|88px|link= Congestive heart failure critical pathways]]|| <br> || <br>
  OMIM          = |
|}
  MedlinePlus    = 000158 |
  eMedicineSubj  = |
  eMedicineTopic = |
  MeshID        = D006333|
}}
{{Congestive heart failure}}
{{Congestive heart failure}}
{{CMG}}
{{CMG}} ; {{AE}} {{EdzelCo}}


==Overview==
== 2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) <ref name="pmid35363499">{{cite journal| author=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM | display-authors=etal| title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2022 | volume= 145 | issue= 18 | pages= e895-e1032 | pmid=35363499 | doi=10.1161/CIR.0000000000001063 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35363499  }} </ref>==


==ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Left Ventricular Dysfunction Due to Prior Myocardial Infarction (DO NOT EDIT) <ref name="pmid16935995">{{cite journal| author=Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al.| title=ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal=Circulation | year= 2006 | volume= 114 | issue= 10 | pages= e385-484 | pmid=16935995 | doi=10.1161/CIRCULATIONAHA.106.178233 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16935995}}</ref>==
===[[Left Ventricular]] [[Dysfunction]] Due to Prior [[Myocardial Infarction]] (DO NOT EDIT) <ref name="pmid16935995">{{cite journal| author=Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al.|title=ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal=Circulation |year= 2006 | volume= 114 | issue= 10 | pages= e385-484 | pmid=16935995 | doi=10.1161/CIRCULATIONAHA.106.178233 | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16935995}}</ref> ===


{|class="wikitable"
{|class="wikitable" style="width:80%"
|-
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class I]]
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class I]]
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Aggressive attempts should be made to treat HF that may be present in some patients with LV dysfunction due to prior MI and [[ventricular tachyarrhythmias]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''. <nowiki>"</nowiki>
| bgcolor="LightGreen"| <nowiki>"</nowiki> '''1.''' Aggressive attempts should be made to treat [[HF]] that may be present in some [[patients]] with [[LV dysfunction]] due to prior [[MI]] and [[ventricular tachyarrhythmia]]s. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Aggressive attempts should be made to treat [[myocardial ischemia]] that may be present in some patients with [[ventricular tachyarrhythmias]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''. <nowiki>"</nowiki>
| bgcolor="LightGreen"| <nowiki>"</nowiki> '''2.''' Aggressive attempts should be made to treat [[myocardial ischemia]] that may be present in some [[patients]] with [[ventricular tachyarrhythmia]]s. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' [[Coronary revascularization]] is indicated to reduce the risk of SCD in patients with VF when direct, clear evidence of acute myocardial ischemia is documented to immediately precede the onset of VF. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''. <nowiki>"</nowiki>
| bgcolor="LightGreen"| <nowiki>"</nowiki> '''3.''' [[Coronary revascularization]] is indicated to reduce the risk of [[SCD]] in [[patients]] with [[VF]] when direct, clear evidence of [[acute myocardial ischemia]] is documented to immediately precede the onset of [[VF]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' If [[coronary revascularization]] cannot be carried out, and there is evidence of prior [[MI]] and significant [[LV dysfunction]], the primary therapy of patients resuscitated from VF should be the ICD in patients who are receiving chronic optimal medical therapy and those who have reasonable expectation of survival with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''. <nowiki>"</nowiki>
| bgcolor="LightGreen"| <nowiki>"</nowiki> '''4.''' If [[coronary revascularization]] cannot be carried out and there is evidence of prior [[MI]] and significant [[LV dysfunction]], the primary [[therapy]] of [[patients]] resuscitated from [[VF]] should be the [[ICD]]] in [[patients]] who are receiving chronic optimal [[medical therapy]] and those who have reasonable expectation of [[survival]] with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''5.''' [[ICD therapy]] is recommended for primary prevention to reduce total mortality by a reduction in SCD in patients with [[LV dysfunction]] due to prior [[MI]] who are at least 40 d post-MI, have an [[LVEF]] less than or equal to 30% to 40%, are NYHA functional class II or III, are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''. <nowiki>"</nowiki>
| bgcolor="LightGreen"| <nowiki>"</nowiki> '''5.''' [[ICD]] therapy is recommended for [[primary prevention]] to reduce total [[mortality]] by a reduction in [[SCD]] in [[patients]] with [[LV dysfunction]] due to prior [[MI]] who are at least 40 d post-[[MI]], have an [[LVEF]] less than or equal to 30% to 40%, are [[NYHA]] functional class II or III, are receiving chronic optimal [[medical therapy]], and who have reasonable expectation of survival with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''6.'''The [[ICD]] is effective therapy to reduce mortality by a reduction in SCD in patients with [[LV dysfunction]] due to prior [[MI]] who present with hemodynamically unstable sustained VT, who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''. <nowiki>"</nowiki>
| bgcolor="LightGreen"| <nowiki>"</nowiki> '''6.''' The [[ICD]] is effective [[therapy]] to reduce [[mortality]] by a reduction in [[SCD]] in [[patients]] with [[LV dysfunction]] due to prior [[MI]] who present with [[hemodynamically]] unstable sustained [[VT]], are receiving chronic optimal [[medical therapy]], and who have reasonable expectation of [[survival]] with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|}
|}


{|class="wikitable"
{|class="wikitable" style="width:80%"
|-
|-
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm)
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class III]]
|-
|-
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Prophylactic antiarrhythmic drug therapy is not indicated to reduce mortality in patients with asymptomatic nonsustained ventricular arrhythmias. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
|bgcolor="LightCoral"| <nowiki>"</nowiki> '''1.''' [[Prophylactic]] [[antiarrhythmic]] [[drug therapy]] is not indicated to reduce [[mortality]] in [[patients]] with [[asymptomatic]] nonsustained [[ventricular arrhythmias]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' [[Antiarrhythmic agent|Class IC antiarrhythmic drugs]] in patients with a past history of [[MI]] should not be used. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
|bgcolor="LightCoral"| <nowiki>"</nowiki> '''2.''' Class IC [[antiarrhythmic drug]]s in [[patients]] with a past [[history]] of [[MI]] should not be used. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|}
|}


{|class="wikitable"
{|class="wikitable" style="width:80%"
|-
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIa]]
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIa]]
|-
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Implantation of an [[ICD]] is reasonable in patients with [[LV dysfunction]] due to prior [[MI]] who are at least 40 d post-MI, have an [[LVEF]] of less than or equal to 30% to 35%, are NYHA functional class I on chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"| <nowiki>"</nowiki> '''1.''' Implantation of an [[ICD]] is reasonable in [[patients]] with [[LV dysfunction]] due to prior [[MI]] who are at least 40 d post-[[MI]], have an [[LVEF]] of less than or equal to 30% to 35%, are [[NYHA]] functional class I on chronic optimal [[medical therapy]], and who have reasonable expectation of [[survival]] with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' [[Amiodarone]], often in combination with [[beta blockers]], can be useful for patients with [[LV dysfunction]] due to prior [[MI]] and symptoms due to VT unresponsive to [[beta-adrenergic blocking agents]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"| <nowiki>"</nowiki> '''2.''' [[Amiodarone]], often in combination with [[beta blockers]], can be useful for [[patients]] with [[LV dysfunction]] due to prior [[MI]] and [[symptoms]] due to [[VT]] unresponsive to [[beta-adrenergic blocking agents]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' [[Sotalol]] is reasonable therapy to reduce symptoms resulting from VT for patients with [[LV dysfunction]] due to prior [[MI]] unresponsive to [[beta blockers|beta-blocking agents]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"| <nowiki>"</nowiki> '''3.''' [[Sotalol]] is reasonable [[therapy]] to reduce [[symptoms]] resulting from [[VT]] for patients with [[LV dysfunction]] due to prior [[MI]] unresponsive to [[beta blocking agents]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''4.''' Adjunctive therapies to the [[ICD]], including [[catheter ablation]] or [[surgical resection]], and pharmacological therapy with agents such as [[amiodarone]] or [[sotalol]] are reasonable to improve symptoms due to frequent episodes of sustained VT or VF in patients with [[LV dysfunction]] due to prior [[MI]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"| <nowiki>"</nowiki> '''4.''' [[Adjunctive therapies]] to the [[ICD]], including [[catheter ablation]] or [[surgical resection]], and [[pharmacological therapy]] with agents such as [[amiodarone]] or [[sotalol]] are reasonable to improve [[symptoms]] due to frequent episodes of [[ustained VT]] or [[VF]] in [[patients]] with [[LV dysfunction]] due to prior [[MI]]. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''5.''' [[Amiodarone]] is reasonable therapy to reduce symptoms due to recurrent hemodynamically stable VT for patients with [[LV dysfunction]] due to prior [[MI]] who cannot or refuse to have an [[ICD]] implanted. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"| <nowiki>"</nowiki> '''5.''' [[Amiodarone]] is reasonable [[therapy]] to reduce [[symptoms]] due to recurrent hemodynamically stable [[VT]] for [[patients]] with [[LV dysfunction]] due to prior [[MI\\ who cannot or refuse to have an [[ICD]] implanted. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''6.''' [[ICD implantation]] is reasonable for treatment of recurrent sustained VT in patients post-MI with normal or near normal ventricular function who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"| <nowiki>"</nowiki> '''6.''' Implantation is reasonable for [[treatment\\ of recurrent [[ventricular tachycardia]] in [[patients]] post-[[MI]] with normal or near normal [[ventricular function]] who are receiving chronic optimal [[medical therapy]] and who have reasonable expectation of [[survival]]] with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|}
|}


{|class="wikitable"
{|class="wikitable" style="width:80%"
|-
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIb]]
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIb]]
|-
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Curative [[catheter ablation]] or [[amiodarone]] may be considered in lieu of [[ICD]] therapy to improve symptoms in patients with [[LV dysfunction]] due to prior [[MI]] and recurrent hemodynamically stable VT whose [[EF]] is greater than 40%. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"| <nowiki>"</nowiki> '''1.''' Curative [[catheter ablation]] or [[amiodarone]] may be considered in lieu of [[ICD therapy]] to improve [[symptoms]] in [[patients]] with [[LV dysfunction]] due to prior [[MI]] and recurrent hemodynamically stable [[VT]] whose [[LVEF]] is greater than 40%. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' [[Amiodarone]] may be reasonable therapy for patients with [[LV dysfunction]] due to prior [[MI]] with an [[ICD]] indication, as defined above, in patients who cannot or refuse to have an [[ICD]] implanted. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|bgcolor="LemonChiffon"| <nowiki>"</nowiki> '''2.''' [[Amiodarone]] may be reasonable [[therapy]] for [[patients]] with [[LV dysfunction]] due to prior [[MI]] with an [[ICD]] indication, as defined above, in patients who cannot or refuse to have an [[ICD]] implanted. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|}
|}
==External Link==
*[https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000001063.full.pdf 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]<ref name="pmid35363499">{{cite journal |vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW |title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines |journal=Circulation |volume=145 |issue=18 |pages=e895–e1032 |date=May 2022 |pmid=35363499 |doi=10.1161/CIR.0000000000001063 |url=}} </ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:Cardiology]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Cardiology]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
 
[[Category:Intensive care medicine]]
{{WikiDoc Help Menu}}
[[Category:Medicine]]
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]

Latest revision as of 22:24, 22 June 2022
Resident
Survival
Guide
File:Critical Pathways.gif

Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure AHA recommendations for patients with a prior MI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure AHA recommendations for patients with a prior MI

CDC on Congestive heart failure AHA recommendations for patients with a prior MI

Congestive heart failure AHA recommendations for patients with a prior MI in the news

Blogs on Congestive heart failure AHA recommendations for patients with a prior MI

Directions to Hospitals Treating Congestive heart failure AHA recommendations for patients with a prior MI

Risk calculators and risk factors for Congestive heart failure AHA recommendations for patients with a prior MI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Edzel Lorraine Co, DMD, MD[2]

2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) [1]

Left Ventricular Dysfunction Due to Prior Myocardial Infarction (DO NOT EDIT) [2]

Class I
" 1. Aggressive attempts should be made to treat HF that may be present in some patients with LV dysfunction due to prior MI and ventricular tachyarrhythmias. (Level of Evidence: C)"
" 2. Aggressive attempts should be made to treat myocardial ischemia that may be present in some patients with ventricular tachyarrhythmias. (Level of Evidence: C)"
" 3. Coronary revascularization is indicated to reduce the risk of SCD in patients with VF when direct, clear evidence of acute myocardial ischemia is documented to immediately precede the onset of VF. (Level of Evidence: B)"
" 4. If coronary revascularization cannot be carried out and there is evidence of prior MI and significant LV dysfunction, the primary therapy of patients resuscitated from VF should be the ICD] in patients who are receiving chronic optimal medical therapy and those who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: A)"
" 5. ICD therapy is recommended for primary prevention to reduce total mortality by a reduction in SCD in patients with LV dysfunction due to prior MI who are at least 40 d post-MI, have an LVEF less than or equal to 30% to 40%, are NYHA functional class II or III, are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: A)"
" 6. The ICD is effective therapy to reduce mortality by a reduction in SCD in patients with LV dysfunction due to prior MI who present with hemodynamically unstable sustained VT, are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: A)"
Class III
" 1. Prophylactic antiarrhythmic drug therapy is not indicated to reduce mortality in patients with asymptomatic nonsustained ventricular arrhythmias. (Level of Evidence: B)"
" 2. Class IC antiarrhythmic drugs in patients with a past history of MI should not be used. (Level of Evidence: A)"
Class IIa
" 1. Implantation of an ICD is reasonable in patients with LV dysfunction due to prior MI who are at least 40 d post-MI, have an LVEF of less than or equal to 30% to 35%, are NYHA functional class I on chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: B) "
" 2. Amiodarone, often in combination with beta blockers, can be useful for patients with LV dysfunction due to prior MI and symptoms due to VT unresponsive to beta-adrenergic blocking agents. (Level of Evidence: B)"
" 3. Sotalol is reasonable therapy to reduce symptoms resulting from VT for patients with LV dysfunction due to prior MI unresponsive to beta blocking agents. (Level of Evidence: C)"
" 4. Adjunctive therapies to the ICD, including catheter ablation or surgical resection, and pharmacological therapy with agents such as amiodarone or sotalol are reasonable to improve symptoms due to frequent episodes of ustained VT or VF in patients with LV dysfunction due to prior MI. (Level of Evidence: C)"
" 5. Amiodarone is reasonable therapy to reduce symptoms due to recurrent hemodynamically stable VT for patients with LV dysfunction due to prior [[MI\\ who cannot or refuse to have an ICD implanted. (Level of Evidence: C)"
" 6. Implantation is reasonable for [[treatment\\ of recurrent ventricular tachycardia in patients post-MI with normal or near normal ventricular function who are receiving chronic optimal medical therapy and who have reasonable expectation of survival] with a good functional status for more than 1 y. (Level of Evidence: C)"
Class IIb
" 1. Curative catheter ablation or amiodarone may be considered in lieu of ICD therapy to improve symptoms in patients with LV dysfunction due to prior MI and recurrent hemodynamically stable VT whose LVEF is greater than 40%. (Level of Evidence: B)"
" 2. Amiodarone may be reasonable therapy for patients with LV dysfunction due to prior MI with an ICD indication, as defined above, in patients who cannot or refuse to have an ICD implanted. (Level of Evidence: C)"

External Link

References

  1. ↑ 1.0 1.1 Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM; et al. (2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (18): e895–e1032. doi:10.1161/CIR.0000000000001063. PMID 35363499 Check |pmid= value (help).
  2. ↑ Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M; et al. (2006). "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (10): e385–484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995.

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Congestive_heart_failure_AHA_recommendations_for_patients_with_a_prior_MI&oldid=1726681"